HK-listed gold stocks jump as US economic fears boost bullion prices
Teladoc Health (NYSE:TDOC) shares rose nearly 2% in premarket trade Thursday after the company said it entered into a pharmacy integration agreement with Eli Lilly (NYSE:LLY)’s LillyDirect pharmacy partner, Gifthealth, to facilitate access to the FDA-approved medication Zepbound (tirzepatide) for participants in its Comprehensive Weight Care Program.
The collaboration aims to provide a more streamlined and affordable option for Teladoc Health members who do not have insurance coverage for GLP-1s for obesity. This integration allows eligible members prescribed Zepbound by their Teladoc Health provider to have the medication delivered directly to their homes.
Teladoc Health’s Comprehensive Weight Care and Primary360 teams will monitor the patient’s medication journey, from dispensing through to delivery and refills, ensuring a transparent and cohesive process.
Kelly Bliss, President of U.S. Group Health at Teladoc Health, emphasized the organization’s commitment to expanding access to evidence-based care, stating, "By integrating with LillyDirect, we are reducing barriers to high-quality care and helping our members afford transformative FDA-approved treatments."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.